New York, New York (PRWEB) July 14, 2013
As Pradaxa lawsuit claims continue to move forward in courts throughout the U.S., Bernstein Liebhard LLP notes that a new study has reported a link between Pradaxa and an increased of risk of heart attacks. The research, presented July 1st at the 2013 Congress of the International Society on Thrombosis and Haemostasis meeting in Amsterdam, the Netherlands, reported that overall, patients taking Pradaxa had a 32% higher risk of suffering a heart attack compared to control groups. However, among those taking the highest dose of the drug – 150 mg – the risk was elevated by 45%. The findings were based on a meta-analysis of 10 studies involving more than 23,000 patients who had been treated with Pradaxa, other therapies or placebo.*
“We hear from individuals on a regular basis who have allegedly suffered frightening and life-threatening episodes of Pradaxa bleeding. This study just serves as a reminder that Pradaxa can be associated with some very serious side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.
Pradaxa was approved in October 2010, and was touted as an improvement over warfarin, a blood thinner that has been in use for decades. Court records indicate that more than 1,100 Pradaxa lawsuits are currently pending in a multidistrict litigation currently underway in U.S. District Court, Southern District of Illinois. All of the claims allege that Boehringer Ingelheim failed to adequately warn about the lack of an antidote for Pradaxa bleeding. The first trial in the Pradaxa side effect litigation is scheduled to start in September 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
According to a recent report from Bloomberg.com, regulators around the world have issued Pradaxa side effect alerts since the drug was launched, most of which have concerned episodes of serious internal bleeding for which there is not a readily available antidote.** Most recently, a study published by the Institute for Safe Medicine Practices (ISMP) reported that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.***
Alleged victims of Pradaxa bleeding may be entitled to compensation for their medical bills, lost wages, pain and suffering and more. Additional information regarding Pradaxa lawsuits is available at Bernstein Liebhard LLP’s website. To arrange for a free legal consultation, please call 800-511-5092.
**bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html , Bloomberg.com, 12-11-2012
***ismp.org/quarterwatch/pdfs/2012Q2.pdf, ISMP January 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com